$HSPOF · Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp. (HSPO), a SPAC, filed an 8-K disclosing a definitive business combination agreement dated October 12, 2026, with ArcheNova Biotech Corp., a clinical-stage biopharmaceutical company developing MSC-derived exosome therapeutics. The deal involves a double-merger structure where HSPO and ArcheNova become wholly-owned subsidiaries of a new Cayman Islands holding company (PubCo), which will apply for Nasdaq listing. No enterprise value, PIPE, or trust-account figures were disclosed in the filing.
- HSPO entered into a definitive business combination agreement with ArcheNova Biotech Corp. on October 12, 2026.
- ArcheNova is a clinical-stage biopharma focused on MSC-derived extracellular vesicle and exosome therapeutics across five indications.
- ArcheNova's lead psoriasis candidate completed a Phase I trial in 10 healthy volunteers and is preparing for Phase II.
- The combined company (PubCo) is expected to list on Nasdaq, with closing targeted for Q1 2027.
- Post-close, PubCo will be led by CEO/Chief Scientist Dr. Lim Sai Kiang and CFO Liu Ye.
Price data unavailable.
A SPAC taking a clinical-stage exosome biotech public with no disclosed valuation leaves investors blind to the deal's core economics until the proxy filing.
This is a SPAC take-public of a preclinical/early-clinical biotech, a structure that has seen mixed post-merger performance. ArcheNova's exosome platform targets regenerative medicine, a field attracting increasing interest but with no approved MSC-exosome products yet.
Transaction may not close due to failure to secure regulatory or shareholder approvals; HSPO's limited operating history and potential redemptions could reduce cash available to the combined company. Nasdaq listing is not guaranteed.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.